The role of EGFR-targeting strategies in the treatment of head and neck cancer.

Onco Targets Ther · 2012 · PMC3412570 · PMID 22888261

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = 0.09so close (0.05 < p ≤ 0.1)

The observed PFS in the control arm was 2.7 months, versus 4.2 months in the cetuximab arm, and this difference did not reach statistical significance ( P = 0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.